NEWS
Free Institutional Consultancy Services
New Feature: Compare Your Institution with the Previous Year
Find a Professional: Explore Experts Across 197 Disciplines in 220 Countries!
Find a Professional
Print Your Certificate
New! Young University / Institution Rankings 2025
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
Highly Cited Researchers 2025
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Reports
person
Find a Professional
David Liu
Washington State University Pullman - Pullman / United States
Others
AD Scientific Index ID: 1361865
Washington State University
Registration, Add Profile,
Premium Membership
Print Your Certificate
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Subject Leaders
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
David Liu's MOST POPULAR ARTICLES
1-)
Scaling of theory‐of‐mind tasksHM Wellman, D LiuChild development 75 (2), 523-541, 200424362004
2-)
Oncogenic signaling pathways in the cancer genome atlasF Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ...Cell 173 (2), 321-337. e10, 201820642018
3-)
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a …ED Kwon, CG Drake, HI Scher, K Fizazi, A Bossi, AJM Van den Eertwegh, ...The lancet oncology 15 (7), 700-712, 201414812014
4-)
A cancer cell program promotes T cell exclusion and resistance to checkpoint blockadeL Jerby-Arnon, P Shah, MS Cuoco, C Rodman, MJ Su, JC Melms, ...Cell 175 (4), 984-997. e24, 201811182018
5-)
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL studyPJ Johnson, S Qin, JW Park, RTP Poon, JL Raoul, PA Philip, CH Hsu, ...Journal of clinical oncology 31 (28), 3517-3524, 20138522013
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept